---
figid: PMC3411967__pnas.1203530S109fig01
figlink: /pmc/articles/PMC3411967/figure/AS-fig01/
number: F1
caption: Cell-proliferative signaling pathways in lung tumors. EGFRs signal through
  the PI3K/AKT and RAS/MEK/ERK cascades. (i) WT EGFRs are activated in a ligand-dependent
  manner. (ii) Mutant EGFRs are constitutively activated. EGFR TKIs block kinase activity
  from mutant EGFRs and inhibit downstream signaling. (A and D) Acquisition of NRAS
  or BRAF mutations (mts) leads to constitutive activation of the RAS/MEK/ERK pathway.
  (B and E) EGFR-TKIs inhibit EGFR, but mutant NRAS or BRAF maintain downstream ERK
  activation. (C) The combination of EGFR and MEK inhibitors can overcome resistance
  caused by the acquisition of NRAS mutations in EGFR-mutant cells. (F) The combination
  of EGFR and BRAF inhibitors or EGFR and MEK inhibitors can overcome resistance caused
  by the acquisition of BRAF mutations in EGFR-mutant cells.
pmcid: PMC3411967
papertitle: Lung cancers with acquired resistance to EGFR inhibitors occasionally
  harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
reftext: Kadoaki Ohashi, et al. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-E2133.
pmc_ranked_result_index: '98217'
pathway_score: 0.851271
filename: pnas.1203530S109fig01.jpg
figtitle: Cell-proliferative signaling pathways in lung tumors
year: '2012'
organisms:
- Homo sapiens
ndex: bd6fb411-de91-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3411967__pnas.1203530S109fig01.html
  '@type': Dataset
  description: Cell-proliferative signaling pathways in lung tumors. EGFRs signal
    through the PI3K/AKT and RAS/MEK/ERK cascades. (i) WT EGFRs are activated in a
    ligand-dependent manner. (ii) Mutant EGFRs are constitutively activated. EGFR
    TKIs block kinase activity from mutant EGFRs and inhibit downstream signaling.
    (A and D) Acquisition of NRAS or BRAF mutations (mts) leads to constitutive activation
    of the RAS/MEK/ERK pathway. (B and E) EGFR-TKIs inhibit EGFR, but mutant NRAS
    or BRAF maintain downstream ERK activation. (C) The combination of EGFR and MEK
    inhibitors can overcome resistance caused by the acquisition of NRAS mutations
    in EGFR-mutant cells. (F) The combination of EGFR and BRAF inhibitors or EGFR
    and MEK inhibitors can overcome resistance caused by the acquisition of BRAF mutations
    in EGFR-mutant cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HRAS
  - MAP2K1
  - MAPK3
  - MAP2K2
  - AKT3
  - AKT1
  - PIK3R3
  - RAF1
  - PIK3CG
  - PIK3CD
  - TIMM8A
  - KRAS
  - BRAF
  - NRAS
  - ARAF
  - PIK3R6
  - EGFR
  - MAPK1
  - PIK3CB
  - PIK3R5
  - AKT2
  - PIK3CA
  - EGF
  - PIK3R4
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: mts
  symbol: MTS
  source: hgnc_alias_symbol
  hgnc_symbol: TIMM8A
  entrez: '1678'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: BR√ÅF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: NRAS
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: EGF)
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC3411967__F1
redirect_from: /figures/PMC3411967__F1
figtype: Figure
---
